A study found that GLP-1 RA use is linked to risks for retained gastric contents during single endoscopic procedures but not ...

Eli Lilly shares are down 11% since president-elect Donald Trump nominated Robert F. Kennedy, Jr. to be Secretary of Health ...

智通财经APP获悉，瑞银发布研究报告称，将信达生物(01801)目标价由60.7港元上调至61.4港元，维持“买入”评级。报告中称，在新型降血糖治疗药物GLP1最近问世之前，在没有便捷、可负担且有效的治疗下，估计内地超重或肥胖症人士当中仅0.1%接受 ...

根据AI大模型测算甘李药业后市走势。短期趋势看，连续3日被主力资金增仓。主力没有控盘。中期趋势方面，上方有一定套牢筹码积压。近期筹码快速出逃，建议调仓换股。舆情分析来看，4家机构预测目标均价68.00，高于当前价44.80%。目前市场情绪极度悲观。

PEIA is proposing a 14 percent increase in premiums, 40 percent in deductibles and increasing the spousal surcharge from to ...

【11 月 20 日，瑞银发布报告】瑞银报告指出，在新型降血糖治疗药物 GLP1 出现前，内地超重或肥胖症人士中仅 0.1%接受临床治疗。GLP-1 临床测试结果及反馈良好，将显著渗透减肥与第二型糖尿病市场，其在后者已有 ...

【11 月 20 日，信达生物(1801.HK)一度涨 8.5%，报 38.95 港元，截至目前成交额放大至 6.2 亿港元。】瑞银称，信达商业化能力强劲，加上 GLP-1 料加大在减肥及二型糖尿病市场，重申“买入”评级，目标价由 60.7 港元上调 1.2%至 61.4 港元。

来凯医疗11月20日午间在港交所公告，该集团已与礼来公司签订一项临床合作协议，旨在支持和加速LAE102针对肥胖症治疗的全球临床开发。礼来将负责在美国执行一项I期研究并承担相关费用。来凯将保留LAE102的全球权益。

Metformin and GLP-1 receptor agonists significantly reduce asthma attacks in patients with type 2 diabetes, offering ...

A groundbreaking Harvard study reveals that semaglutide could benefit more people in the U.S. than ever imagined.

An estimated one in ten Americans have been on a GLP-1. Some 12% — or about 1 in 8 — people living in the U.S. have tried a GLP-1 drug, according to a survey by the Kaiser Family Foundation. And with ...

Driving business growth through innovative food and nutrition strategies for CPG & foodservice brands. 💡 The Rise of GLP-1 ...